

Pronační poloha

- good end of a long story

Stibor B.


ICU, Landeskrankenhaus Baden bei Wien, Austria

no conflict of interest

Stibor B.

ICU, Landeskrankenhaus Baden bei Wien, Austria

přehled

1. ARDS
 2. léčebné modality
 3. pronační poloha – historie, studie
 4. mechanismus účinku pronace
 5. indikace, kontraindikace, podmínky
 6. praktické provedení pronace
 7. pronace a ... ?
- 



ARDS



(F)

Abstrahlungsmaßnahme

11.11.2011 21:29:09


06.06.1981

dgf.:21:29:09

PatID: 0195721499

Cor pulmo

CP ap



20mm
approx

Plate ID:I5209L
Thermenklinikum BADEN

Agfa
CR 75

(F)

25.10.2011 10:36:11

06.06.1981


dgf.:10:36:11

PatID: 0195721499

Bettaufnahme

Cor pulmo

CP ap



20mm
approx

Plate ID: I5209L
Thermenklinikum BADEN

Agfa
CR 75

***léčebné
modality***

ventilation options in ARDS

lung protective ventilation

- lower tidal volume
- higher PEEP
- $P_{\text{plateau}} < 30 \text{ mm Hg}$
- $\text{FiO}_2 < 0,60$

inverse ratio ventilation IRV

open lung concept


baby lung concept, permissive hypercapny

non-ventilation options in ARDS

- pronační poloha
- extrakorporální oxygenace a CO₂ eliminace

- HFOV
- inhalace NO
- *others ...*

Increasing intensity of intervention



with courtesy of M. V. Ranieri

***pronační
poloha***

pronační poloha

- ✓ „*prone position*“, „*Bauchlage*“
- ✓ poloha vleže na břicho
- ✓ v souvislosti s plicní patologií se používá u těžkého akutního respiračního selhání (*severe ARDS*)




***historie,
studie***

historie

Use of extreme position changes in acute respiratory failure

Piehl et al. Crit Care Med;1976;4:13-14.

- 5 pacientů s ARDS
- při UPV nutné $\text{FiO}_2 > 0,60$
- těžká hypoxémie před UPV ($\text{P}_a\text{O}_2 < 50 \text{ mmHg}$)
- otáčení pomocí CircOlectric Bed



.... poprvé použita před 38 lety


studie



Effect of prone positioning on the the survival of patients with acute respiratory failure

Gattinoni et al. N Engl J Med;2001;345:568-73.

- 304 pacientů s ARDS
- délka pronace $7,0 \pm 1,8$ h/day
- zlepšení oxygenace (P_aO_2/FiO_2)
- není rozdíl v mortalitě
- post hoc analýza:*




.... 响 10d mortality u nejtěžších ARDS

studie

Multicenter trial of prolonged prone ventilation in severe ARDS

Mancebo et al. Am J Respir Crit Care Med;2006;173:1233-9.

- 136 pacientů s ARDS
- délka pronace ≈ 17 h/day
- zlepšení oxygenace (P_aO_2/FiO_2)
- snížení ICU mortality



... may reduce mortality when it is initiated early and applied for most of the day ...


studie



Prone positioning improves survival in severe ARDS: a review and meta-analysis

Gattinoni et al. Minerva Anestesiol;2010;76:448-54.

- four major clinical trials
- 1573 patients
- moderate hypoxemia (200-100mmHg)
- severe hypoxemia (<100mmHg)



No. at risk	
Prone	226 98 80 71 41 40 40
Supine	260 128 140 93 55 54 54

... **absolute mortality** of severely hypoxemic ARDS patients may be **reduced** by approximately **10%** ($p < 0,05$)

An updated study-level meta-analysis of randomised controlled trials on proning in ARDS and acute lung injury

Fekri Abroug^{1*}, Lamia Ouane-Besbes¹, Fahmi Dachraoui¹, Islem Ouane¹, Laurent Brochard^{2,3,4}

Abstract

Introduction: In patients with acute lung injury (ALI) and/or acute respiratory distress syndrome (ARDS), recent randomised controlled trials (RCTs) showed a consistent trend of mortality reduction with prone ventilation. We updated a meta-analysis on this topic.

Methods: RCTs that compared ventilation of adult patients with ALI/ARDS in prone versus supine position were included in this study-level meta-analysis. Analysis was made by a random-effects model. The effect size on intensive care unit (ICU) mortality was computed in the overall included studies and in two subgroups of studies: those that included all ALI or hypoxemic patients, and those that restricted inclusion to only ARDS patients. A relationship between studies' effect size and daily prone duration was sought with meta-regression. We also computed the effects of prone positioning on major adverse airway complications.

Results: Seven RCTs (including 1,675 adult patients, of whom 862 were ventilated in the prone position) were included. The four most recent trials included only ARDS patients, and also applied the longest proning durations and used lung-protective ventilation. The effects of prone positioning differed according to the type of study. Overall, prone ventilation did not reduce ICU mortality (odds ratio = 0.91, 95% confidence interval = 0.75 to 1.2; $P = 0.39$), but it significantly reduced the ICU mortality in the four recent studies that enrolled only patients with ARDS (odds ratio = 0.71; 95% confidence interval = 0.5 to 0.99; $P = 0.048$; number needed to treat = 11). Meta-regression on all studies disclosed only a trend to explain effect variation by prone duration ($P = 0.06$). Prone positioning was not associated with a statistical increase in major airway complications.

Conclusions: Long duration of ventilation in prone position significantly reduces ICU mortality when only ARDS patients are considered.

debate continues...

con



M. Amato

pro



L. Gattinoni

studie

PROSEVA trial: Effect of prone positioning in patients with severe and persistent ARDS.

Guérin Claude, presented at ESICM Congress, Lisboa 2012

- multicenter French + Spanisch
- $p_aO_2/FiO_2 < 150$
- $FiO_2 \geq 0,60$, PEEP ≥ 5 , Vt 6 ml/kg
- 460 pts, prone > 16h/day
- 28-day mortality
- 90-day mortality, incidence of VAP



The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

JUNE 6, 2013

VOL. 368 NO. 23


Prone Positioning in Severe Acute Respiratory Distress Syndrome

RESULTS

A total of 237 patients were assigned to the prone group, and 229 patients were assigned to the supine group. The 28-day mortality was 16.0% in the prone group and 32.8% in the supine group (P<0.001). The hazard ratio for death with prone positioning was 0.39 (95% confidence interval [CI], 0.25 to 0.63). Unadjusted 90-day mortality was 23.6% in the prone group versus 41.0% in the supine group (P<0.001), with a hazard ratio of 0.44 (95% CI, 0.29 to 0.67). The incidence of complications did not differ significantly between the groups, except for the incidence of cardiac arrests, which was higher in the supine group.

Table 3. Primary and Secondary Outcomes According to Study Group.*

Outcome	Supine Group (N = 229)	Prone Group (N = 237)	Hazard Ratio or Odds Ratio with the Prone Position (95% CI)	P Value
Mortality — no. (% [95% CI])				
At day 28				
Not adjusted	75 (32.8 [26.4–38.6])	38 (16.0 [11.3–20.7])	0.39 (0.25–0.63)	<0.001
Adjusted for SOFA score†			0.42 (0.26–0.66)	<0.001
At day 90				
Not adjusted	94 (41.0 [34.6–47.4])	56 (23.6 [18.2–29.0])	0.44 (0.29–0.67)	<0.001
Adjusted for SOFA score†			0.48 (0.32–0.72)	<0.001
Successful extubation at day 90 — no./total no. (% [95% CI])	145/223 (65.0 [58.7–71.3])	186/231 (80.5 [75.4–85.6])	0.45 (0.29–0.70)	<0.001
Time to successful extubation, assessed at day 90 — days				
Survivors	19±21	17±16		0.87
Nonsurvivors	16±11	18±14		
Length of ICU stay, assessed at day 90 — days				
Survivors	26±27	24±22		0.05
Nonsurvivors	18±15	21±20		
Ventilation-free days				
At day 28	10±10	14±9		<0.001
At day 90	43±38	57±34		<0.001



No. at Risk

Prone group	237	202	191	186	182
Supine group	229	163	150	139	136




Figure 2. Kaplan–Meier Plot of the Probability of Survival from Randomization to Day 90.

mechanismus
účinku

pronační poloha

- ✓ recruitment dorsálních (atelektatických) partií
- ✓ homogenizace ventilačně-perfúzních nepoměrů
- ✓ 响 intrapulmonálních pravolevých zkratů
- ✓ vzestup funkční reziduální kapacity

zlepšení oxygenace



pozitivní efekty

- ✓ zlepšení oxygenace
- ✓ drenážní plicní poloha (mobilizace sekretu z DC)
- ✓ snížení incidence VAP
- ✓ snížení rizika dorsálních dekubitů

snížení mortality

typy pronace

intermitentní dorsoventrální polohování

- 180° 2 x denně

kontinuální axiální rotace

- *RotoRest*

intermitentní jednostranné polohování

- „down with the good lung“, *Fischman, 1981*

přetočená poloha 135°

kdy do pronační polohy?

- ✓ těžká porucha oxygenace (*severe ARDS*)
- ✓ Horowitz index $P_aO_2/FiO_2 < 100$ (150) mmHg

protektivní ventilační režim

nutnost $FiO_2 \geq 0,60$

kontraindikace

- ✓ akutní fáze KCP (倻ICP)
- ✓ nestabilní úrazy páteře
- ✓ těžká akutní kardiovaskulární instabilita, ev. maligní arytmie
- ✓ bezprostředně po hrudní či abdominální operaci

jak dlouho pronaci?

délka pronace souvisí
se snížením mortality

7 – 10 h/day?

12 – 14 h/day?

20 – 24 h/day?

20 – 24 h/day

pronace a typ ARDS

primární

pozitivní vliv později
(odstup až 12 h)

sekundární

pozitivní vliv dříve
(odstup 1-3 h)


kdy ukončit pronaci?

- ✓ pacient je *nonrespondent*
- ✓ zlepšení klinického stavu
- ✓ snížení agresivity ventilace
- ✓ snížení FiO_2 na 0,60 a méně

***praktické
provedení***

provedení

- ✓ otočení trvá cca 10 – 15 min
- ✓ potřeba 3 osoby (*2 v nouzi*)
- ✓ cave:
 - ✓ endotracheální či tracheostomická kanyla
 - ✓ cévní vstupy (CVK, *artery line*, PiCCO...)
 - ✓ jiné vstupy (NGS, PEG sonda, močový katetr, drenáže, hrudní sání...)
- ✓ *přítomnost lékaře na ICU*



























CiMON

PULSION
Medical Systems

03 Jan 2010 17:20:11

MESSUNG



STERILE R

A-7041-0033-0

E38/Feld2/9e5

pronace ovlivňuje

- ✓ vnitřní prostředí
- ✓ parametry UPV

↓ pronace

														02.01.2010					10	
	11	12	13	14	15	16	17	18	19	20	21	22	23	00	01	02	03	04	05	
Respirator Eins																				
Hamilton Mod	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV
FIO ² (s) %	90	90	80	70	70	70	70	65	65	65	65	65	60	60	60	60	60	60	60	60
% Min. Vol. %																				
MVset l/min																				
TV set ml																				
... ..																				
I:E(s)	1,52	1,52	1,52	1,52	1,52	1,52	1,52	1,52	1,52	1,52	1,52	1,52	1,52	1,52	1,52	1,52	1,52	1,52	1,52	1,52
Tinsp set %																				
.....																				
Paw (s) cmH2O																				
PS set cmH2O	15																			
PEEP2(s) cmH2O	18	19	19	19	19	19	19	19	19	19	19	19	19	19	19	19	19	19	19	19
PEEP(s) cmH2O	17	17	17	17	17	17	17	17	17	17	17	17	17	17	17	17	17	17	17	17
.....																				
ETS %	25																			
Druckrampe msec	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50
Respirator Meß																				
Hamilton Mod	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV
FIO ² (m) %	90	89	80	70	70	70	70	65	65	65	65	65	60	61	61	60	61	61	61	61
f total /min	15	16	16	16	16	16	16	16	16	16	16	16	16	16	16	16	16	16	16	16
f spontan /min	0																			
AF(CO ₂) /min																				
AF(EKG) /min	15	15	15																	
.....																				
SpO ₂ %	97	98	100	97	97	98	98	97	98	98	98	98	97	97	97	97	97	97	97	98
ETCO ₂ mmHg																				
.....																				
I:E(m)	1,49	1,49	1,49	1,49	1,49	1,49	1,49	1,49	1,49	1,49	1,49	1,49	1,49	1,49	1,49	1,49	1,49	1,49	1,49	1,49
Tinsp(m) s	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
Texp(m) s	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2
.....																				
Ppeak (m) cmH2O	38	37	38	38	38	38	38	38	38	38	38	38	38	38	39	38	38	38	38	38
PEEP(m) cmH2O	15	17	17	17	17	17	17	17	17	17	17	17	17	17	17	17	17	17	17	17
PEEPint cmH2O	0,0	0,0	0,0					4,0	0,0	2,0	1,0		7,0	1,0						6,0
.....																				
VTinsp(m) ml	542	740	669	709	709	708	701	857	785	773	728	755	760	736	767	762	774	760	774	
VTemp(m) ml	538	729	647	679	669	669	669	769	784	739	694	707	709	708	742	726	718	725	747	
ExpMinVol l/min	8,1	10,7	10,3	10,8	10,7	10,7	10,7	12,7	11,6	11,6	11,4	11,7	11,6	11,4	11,9	11,7	11,7	11,7	11,8	
.....																				
InspFlow l/min	60,0	53,0	55,0	59,0	60,0	60,0	60,0	61,0	62,0	61,0	62,0	64,0	64,0	63,0	64,0	64,0	65,0	64,0	64,0	
ExpFlow l/min	67,4	67,5	69,8	69,9	69,7	69,4	69,0	70,1	71,6	71,5	71,6	72,4	71,2	72,1	73,7	72,8	73,0	72,0	75,1	
Compl stat ml/cmH2O	30	41	38	38	38	38	38	48	47	48	47	48	48	38	39	39	40	39	40	
Resistance cmH2O/M	5	9	7	8	7	7	7	6	8	7	7	6	6	6	6	6	6	6	5	
Blutgasanalyse																				
#PHI	7,030			7,246	7,265	7,269						7,317			7,317				7,328	7,328

pronace

02.01.2010

11 12 13 14 15 16 17 18 19 20 21 22 23 00 01 02 03 04 05 Gesa

Blutgasanalyse

#PHI	7,030			7,246	7,265	7,269						7,317			7,317				7,328
#PCO2l mmHg	111,0			58,8	56,4	55,5						51,3			52,4				51,5
#PO2l mmHg	103,0			148,0	108,0	129,0						128,0			112,0				118,0
#HCO3l mmol/l	20,5			22,8	22,8	22,7						24,7			24,5				24,9
#SBEI mmol/l	-2,0			-1,7	-1,3	-1,4						0,1			0,6				1,0
#SO2l %	96,4			99,7	98,9	99,4						99,5			99,0				99,2
#CNAI mmol/l	141			140	139	140						139			141				139
#CKI mmol/l	4,8											4,4			4,4				4,3
#CCAI mmol/l	1,25											1,8			1,21				1,18
#CCLI mmol/l	103											102			102				102
#CTHBI g/dl	9,9											9,6			9,6				9,8
#HCTI %	30,6											29,6			29,7				30,3
#BZI mg/dl	205											15			115				101
#LAK-I mmol/l	1,4											1,5			1,3				1,2
#MOSMI mmol/kg	293,2											5,2			287,6				283,3
#O2HBI %	94,4			97,1	96,1	96,6						96,8			96,8				97,0
#COHBI %	1,8			2,0	2,1	2,0						2,0			1,8				1,7
#METHBI %	0,3			0,6	0,7	0,8						0,7			0,4				0,5
#AGAPI mmol/l	9,8			12,9	11,6	13,0						10,8			12,8				10,4
#AGAPKI mmol/l	14,6			18,1	16,5	17,7						15,3			17,2				14,7
#CTO2l VOL%	13,3			13,6	13,6	13,2						13,3			13,2				13,6
#CTCO2l VOL%	64,5			53,3	53,0	52,9						54,3			55,4				55,7
#P50l mmHg	33,04			30,93	30,23	30,09						28,60			28,77				28,44
#TEMPI °C	38,0			37,4	37,5	37,4						37,0			37,0				37,0
Blutzucker mg/dl																			94
#Probyte	art.			art.	art.	art.						art.			art.				art.

pH	7,030	7,246
pCO2 (mmHg)	111,0	58,8
pO2 (mmHg)	103,0	148,0

Hamilton Mod	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV	PCMV
FIO2(s) %	90	90	80	70	70	70	70	65	65	65	65	65	60	60	60	60	60	60	60
I:E(s)	1,52	1,52	1,52	1,52	1,52	1,52	1,52	1,52	1,52	1,52	1,52	1,52	1,52	1,52	1,52	1,52	1,52	1,52	1,52
ASB(s) mbar																			
PEEP(s) cmH2O	17	17	17	17	17	17	17	17	17	17	17	17	17	17	17	17	17	17	17
TV set ml																			
ETS %	25																		
PIP (set) mmHg																			
MVset l/min																			
% Min. Vol. %																			
Tinsp set %																			
Tinsp pause %																			
PeakFlow l/min																			
FlowPattern																			
TriggerType	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0
Trigger cmH2O																			
FIO2(m) %	90	89	80	70	70	70	70	65	65	65	65	65	60	61	61	60	61	61	61

pronace


a

... ?

pronace a ...

- ✓ enterální výživa
- ✓ CRRT
- ✓ tracheotomie
- ✓ bronchofibroskopie
- ✓ resuscitace
- ✓ *ostatní ...*











to take home message:

- pronaci používat rutinně u **těžkého** ARDS
- vhodný druh pronace (**135°**)
- nasadit **včas** ($\text{FiO}_2 > 0,60$ při protekci)
- ponechat **déle** (17 – 22 h/day)
- *zaškolit **personál***

↑↑oxygenace, ↓snížení mortality



Cicero

„Don't speak longer in
public
than you can make love in
private.“

...děkuji Vám za pozornost

